Annual EBITDA
-$204.54 M
-$62.58 M-44.08%
December 31, 2023
Summary
- As of February 7, 2025, COGT annual EBITDA is -$204.54 million, with the most recent change of -$62.58 million (-44.08%) on December 31, 2023.
- During the last 3 years, COGT annual EBITDA has fallen by -$169.97 million (-491.69%).
- COGT annual EBITDA is now -3089.49% below its all-time high of -$6.41 million, reached on December 31, 2015.
Performance
COGT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$74.32 M
-$11.01 M-17.39%
September 30, 2024
Summary
- As of February 7, 2025, COGT quarterly EBITDA is -$74.32 million, with the most recent change of -$11.01 million (-17.39%) on September 30, 2024.
- Over the past year, COGT quarterly EBITDA has dropped by -$11.01 million (-17.39%).
- COGT quarterly EBITDA is now -3009.83% below its all-time high of $2.55 million, reached on December 31, 2019.
Performance
COGT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$256.40 M
-$15.59 M-6.47%
September 30, 2024
Summary
- As of February 7, 2025, COGT TTM EBITDA is -$256.40 million, with the most recent change of -$15.59 million (-6.47%) on September 30, 2024.
- Over the past year, COGT TTM EBITDA has dropped by -$15.59 million (-6.47%).
- COGT TTM EBITDA is now -4327.49% below its all-time high of -$5.79 million, reached on March 31, 2017.
Performance
COGT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
COGT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -44.1% | -17.4% | -6.5% |
| 3 y3 years | -491.7% | -285.0% | -328.0% |
| 5 y5 years | -489.7% | -944.2% | -1058.8% |
COGT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -178.1% | at low | -196.2% | at low | -248.6% | at low |
| 5 y | 5-year | -562.3% | at low | -3009.8% | at low | -1146.1% | at low |
| alltime | all time | -3089.5% | at low | -3009.8% | at low | -4327.5% | at low |
Cogent Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$74.32 M(+17.4%) | -$256.40 M(+6.5%) |
| Jun 2024 | - | -$63.31 M(+3.2%) | -$240.80 M(+7.8%) |
| Mar 2024 | - | -$61.34 M(+6.8%) | -$223.37 M(+9.2%) |
| Dec 2023 | -$204.54 M(+44.1%) | -$57.43 M(-2.2%) | -$204.54 M(+7.7%) |
| Sep 2023 | - | -$58.73 M(+28.0%) | -$189.92 M(+15.6%) |
| Jun 2023 | - | -$45.87 M(+7.9%) | -$164.30 M(+7.0%) |
| Mar 2023 | - | -$42.51 M(-0.7%) | -$153.62 M(+8.2%) |
| Dec 2022 | -$141.96 M(+93.0%) | -$42.81 M(+29.3%) | -$141.96 M(+14.3%) |
| Sep 2022 | - | -$33.11 M(-5.9%) | -$124.25 M(+12.5%) |
| Jun 2022 | - | -$35.19 M(+14.0%) | -$110.44 M(+20.5%) |
| Mar 2022 | - | -$30.86 M(+23.0%) | -$91.64 M(+24.6%) |
| Dec 2021 | -$73.56 M(+112.8%) | -$25.09 M(+30.0%) | -$73.56 M(+22.8%) |
| Sep 2021 | - | -$19.30 M(+17.9%) | -$59.91 M(+18.0%) |
| Jun 2021 | - | -$16.38 M(+28.1%) | -$50.77 M(+22.3%) |
| Mar 2021 | - | -$12.78 M(+11.7%) | -$41.51 M(+20.1%) |
| Dec 2020 | -$34.57 M | -$11.44 M(+12.5%) | -$34.57 M(+68.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$10.17 M(+42.9%) | -$20.58 M(-7.0%) |
| Jun 2020 | - | -$7.12 M(+21.7%) | -$22.13 M(-12.3%) |
| Mar 2020 | - | -$5.85 M(-328.9%) | -$25.22 M(-18.3%) |
| Dec 2019 | -$30.89 M(-11.0%) | $2.55 M(-121.8%) | -$30.89 M(-26.6%) |
| Sep 2019 | - | -$11.72 M(+14.8%) | -$42.09 M(+3.6%) |
| Jun 2019 | - | -$10.21 M(-11.3%) | -$40.62 M(+2.8%) |
| Mar 2019 | - | -$11.51 M(+33.0%) | -$39.52 M(+14.0%) |
| Dec 2018 | -$34.68 M(+38.8%) | -$8.65 M(-15.6%) | -$34.68 M(+6.4%) |
| Sep 2018 | - | -$10.25 M(+12.4%) | -$32.60 M(+11.6%) |
| Jun 2018 | - | -$9.11 M(+36.6%) | -$29.23 M(+13.0%) |
| Mar 2018 | - | -$6.67 M(+1.5%) | -$25.86 M(+3.5%) |
| Dec 2017 | -$24.98 M(+37.0%) | -$6.57 M(-4.3%) | -$24.98 M(+35.7%) |
| Sep 2017 | - | -$6.87 M(+19.5%) | -$18.41 M(+59.5%) |
| Jun 2017 | - | -$5.75 M(-0.8%) | -$11.54 M(+99.2%) |
| Mar 2017 | - | -$5.79 M | -$5.79 M |
| Dec 2016 | -$18.24 M(+184.4%) | - | - |
| Dec 2015 | -$6.41 M | - | - |
FAQ
- What is Cogent Biosciences annual EBITDA?
- What is the all time high annual EBITDA for Cogent Biosciences?
- What is Cogent Biosciences annual EBITDA year-on-year change?
- What is Cogent Biosciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cogent Biosciences?
- What is Cogent Biosciences quarterly EBITDA year-on-year change?
- What is Cogent Biosciences TTM EBITDA?
- What is the all time high TTM EBITDA for Cogent Biosciences?
- What is Cogent Biosciences TTM EBITDA year-on-year change?
What is Cogent Biosciences annual EBITDA?
The current annual EBITDA of COGT is -$204.54 M
What is the all time high annual EBITDA for Cogent Biosciences?
Cogent Biosciences all-time high annual EBITDA is -$6.41 M
What is Cogent Biosciences annual EBITDA year-on-year change?
Over the past year, COGT annual EBITDA has changed by -$62.58 M (-44.08%)
What is Cogent Biosciences quarterly EBITDA?
The current quarterly EBITDA of COGT is -$74.32 M
What is the all time high quarterly EBITDA for Cogent Biosciences?
Cogent Biosciences all-time high quarterly EBITDA is $2.55 M
What is Cogent Biosciences quarterly EBITDA year-on-year change?
Over the past year, COGT quarterly EBITDA has changed by -$11.01 M (-17.39%)
What is Cogent Biosciences TTM EBITDA?
The current TTM EBITDA of COGT is -$256.40 M
What is the all time high TTM EBITDA for Cogent Biosciences?
Cogent Biosciences all-time high TTM EBITDA is -$5.79 M
What is Cogent Biosciences TTM EBITDA year-on-year change?
Over the past year, COGT TTM EBITDA has changed by -$15.59 M (-6.47%)